Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on October 19, 2006

Arteriosclerosis, Thrombosis, and Vascular Biology. 2006
Published online before print October 19, 2006, doi: 10.1161/01.ATV.0000250615.27795.85
A more recent version of this article appeared on January 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
27/1/226    most recent
01.ATV.0000250615.27795.85v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cappello, C.
Right arrow Articles by Brand, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cappello, C.
Right arrow Articles by Brand, K.

Submitted on November 12, 2005
Accepted on September 28, 2006

Ozonized Low Density Lipoprotein (ozLDL) Inhibits NF-{kappa}B and IRAK-1-Associated Signaling

Christian Cappello ; Bernd Saugel ; Karin C. Huth ; Andreas Zwergal ; Martina Krautkrämer ; Christophe Furman ; Mustapha Rouis ; Bianca Wieser ; Heike W. Schneider ; Dieter Neumeier ; and Korbinian Brand *

From the Institute of Clinical Chemistry and Pathobiochemistry (C.C., B.S., A.Z., M.K., B.W., H.W.S., D.N., K.B.), Klinikum rechts der Isar, Technische Universität München, Germany; the Department of Restorative Dentistry and Periodontology (K.C.H.), Ludwig-Maximilians-Universität München, Germany; and INSERM U-545 and Institut Pasteur de Lille (C.F., M.R.), Lille Cedex, France.

* To whom correspondence should be addressed. E-mail: brand{at}klinchem.med.tum.de.

Objective--Recent studies have provided strong evidence for the presence of ozone in atherosclerotic lesions. In addition, modification of LDL has been suggested to be involved in atherosclerosis. In the present study we wanted to investigate whether LDL exposed to ozone (ozLDL) is able to modulate the NF-{kappa}B system, as a paradigm for inflammatory signaling.

Methods and Results--We showed that activation of NF-{kappa}B by lipopolysaccharide (LPS), a prototypic inducer of innate immunity, was reversibly inhibited by ozLDL in monocytic THP-1 cells in a dose-dependent manner, whereas tumor necrosis factor (TNF) signaling was not affected. This was not attributable to a direct ozone effect or solely the presence of lipoprotein, and neither required direct contact to LPS nor was accompanied by a change in LPS binding. Comparable inhibitory effects of ozLDL were observed in human monocyte/macrophages and endothelial cells. The presence of ozLDL led to a decrease in LPS-induced {iota}{kappa}B{alpha} proteolysis and a reduction of {kappa}B-dependent transcription/target-gene expression. Furthermore, ozLDL markedly lowered stimulus-induced {iota}{kappa}B kinase (IKK) activity and phosphorylation/proteolysis of interleukin (IL)-1 receptor-associated kinase-1 (IRAK-1). Finally, cholesterol ozonization products were identified as effective ozLDL inhibitory compounds.

Conclusion--Our study demonstrated that ozLDL inhibited NF-{kappa}B and IRAK-1-associated signaling which may impair immune function and promote apoptosis.


Key words: ozone • ozonized LDL • atherosclerosis • NF-{kappa}B • IRAK-1




This article has been cited by other articles:


Home page
Proc Am Thorac SocHome page
J. W. Hollingsworth, S. R. Kleeberger, and W. M. Foster
Ozone and Pulmonary Innate Immunity
Proceedings of the ATS, July 1, 2007; 4(3): 240 - 246.
[Abstract] [Full Text] [PDF]